AI assistant
Monopar Therapeutics — Director's Dealing 2022
Apr 1, 2022
32883_dirs_2022-04-01_959d6c20-4cd7-4813-a612-4349f472ec6d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2022-03-31
Reporting Person: Tsuchimoto Kim R (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-31 | Common Stock | M | 1221 | — | Acquired | 6136 | Direct |
| 2022-03-31 | Common Stock | F | 500 | $2.55 | Disposed | 5636 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | Restricted Stock Units | $ | M | 1221 | Disposed | Common Stock (1221) | Direct |
Footnotes
F1: Represents shares acquired on vesting and settlement of restricted stock units.
F2: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.